Tatiana A. Slastnikova

Tatiana A. Slastnikova

Auto-generated profile, based on publicly available information

Tatiana A. Slastnikova

Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
TSTatiana Slastnikova
Tatiana Slastnikova
ARAndrey A Rosenkranz
Andrey A Rosenkranz
YKYuri V Khramtsov
Yuri V Khramtsov
TKTatiana S Karyagina
Tatiana S Karyagina
SOSergey Ovechko
Sergey Ovechko
Alexander S. SobolevAlexander S. Sobolev
Alexander S. Sobolev
Purpose: Modular nanotransporters (MNTs) are artificial multifunctional systems designed to facilitate receptor-specific transport from the cell surface into the cell nucleus through inclusion of polypeptide domains for accomplishing receptor binding and internalization, as well as sequential endosomal escape and nuclear translocation. The objective of this study was to develop a new MNT targeted at folate receptors (FRs) for precise delivery of therapeutic cargo to the nuclei of FR-positive cells and to evaluate its potential, particularly for delivery of therapeutic agents (eg, the Auger electron emitter 111In) into the nuclei of target cancer cells. Methods: A FR-targeted MNT was developed by site-specific derivatization of ligand-free MNT with maleimide-polyethylene glycol-folic acid. The ability of FR-targeted MNT to accumulate in target FR-expressing cells was evaluated using flow cytometry, and intracellular localization of this MNT was assessed using confocal laser scanning microscopy of cells. The cytotoxicity of the 111In-labeled FR-targeted MNT was evaluated on HeLa and U87MG cancer cell lines expressing FR. In vivo micro-single-photon emission computed tomography/CT imaging and antitumor efficacy studies were performed with intratumoral injection of 111In-labeled FR-targeted MNT in HeLa xenograft-bearing mice. Results: The resulting FR-targeted MNT accumulated in FR-positive HeLa cancer cell lines specifically and demonstrated the ability to reach its target destination – the cell nuclei. 111In-labeled FR-targeted MNT demonstrated efficient and specific FR-positive cancer cell eradication. A HeLa xenograft in vivo model revealed prolonged retention of 111In delivered by FR-targeted MNT and significant tumor growth delay (up to 80% growth inhibition). Conclusion: The FR-targeted MNT met expectations of its ability to deliver active cargo into the nuclei of target FR-positive cells efficiently and specifically. As a result of this finding the new FR-targeted MNT approach warrants broad evaluation.

1 January 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
TSTatiana Slastnikova
Tatiana Slastnikova
ARAndrey A Rosenkranz
Andrey A Rosenkranz
NMNatalya Morozova
Natalya Morozova
MVMaria S Vorontsova
Maria S Vorontsova
VPVasiliy M Petriev
Vasiliy M Petriev
Alexander S. SobolevAlexander S. Sobolev
Alexander S. Sobolev
Purpose: Modular nanotransporters (MNTs) are a polyfunctional platform designed to achieve receptor-specific delivery of short-range therapeutics into the cell nucleus by receptor-mediated endocytosis, endosome escape, and targeted nuclear transport. This study evaluated the potential utility of the MNT platform in tandem with Auger electron emitting 111In for cancer therapy. Methods: Three MNTs developed to target either melanocortin receptor-1 (MC1R), folate receptor (FR), or epidermal growth factor receptor (EGFR) that are overexpressed on cancer cells were modified with p-SCN-Bn-NOTA and then labeled with 111In in high specific activity. Cytotoxicity of the 111In-labeled MNTs was evaluated on cancer cell lines bearing the appropriate receptor target (FR: HeLa, SK-OV-3; EGFR: A431, U87MG.wtEGFR; and MC1R: B16-F1). In vivo micro-single-photon emission computed tomography/computed tomography imaging and antitumor efficacy studies were performed with intratumoral injection of MC1R-targeted 111In-labeled MNT in B16-F1 melanoma tumor-bearing mice. Results: The three NOTA-MNT conjugates were labeled with a specific activity of 2.7 GBq/mg with nearly 100% yield, allowing use without subsequent purification. The cytotoxicity of 111In delivered by these MNTs was greatly enhanced on receptor-expressing cancer cells compared with 111In nontargeted control. In mice with B16-F1 tumors, prolonged retention of 111In by serial imaging and significant tumor growth delay (82% growth inhibition) were found. Conclusion: The specific in vitro cytotoxicity, prolonged tumor retention, and therapeutic efficacy of MC1R-targeted 111In-NOTA–MNT suggest that this Auger electron emitting conjugate warrants further evaluation as a locally delivered radiotherapeutic, such as for ocular melanoma brachytherapy. Moreover, the high cytotoxicity observed with FR- and EGFR-targeted 111In-NOTA–MNT suggests further applications of the MNT delivery strategy should be explored.

5 November 2019 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
Roman Y. PishchalnikovRoman Y. Pishchalnikov
Roman Y. Pishchalnikov
IYIgor A. Yaroshevich
Igor A. Yaroshevich
TSTatiana A. Slastnikova
Tatiana A. Slastnikova
AAAleksandr Ashikhmin
Aleksandr Ashikhmin
ASAlexey V. Stepanov
Alexey V. Stepanov
Eugene G. MaksimovEugene G. Maksimov
Eugene G. Maksimov
Comparative study of spectroscopic features reveals the structural determinants of keto-carotenoids in photoactive water-soluble proteins.

1 September 2012 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Open access
PDF file
TST. A. Slastnikova
T. A. Slastnikova
ARAndrey A Rosenkranz
Andrey A Rosenkranz
TLTatiana N. Lupanova
Tatiana N. Lupanova
PGP. V. Gulak
P. V. Gulak
NGN. V. Gnuchev
N. V. Gnuchev
Alexander S. SobolevAlexander S. Sobolev
Alexander S. Sobolev

14 September 2020 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
ARAndrey A Rosenkranz
Andrey A Rosenkranz
TSTatiana A. Slastnikova
Tatiana A. Slastnikova
MDMikhail Durymanov
Mikhail Durymanov
GGGeorgii P. Georgiev
Georgii P. Georgiev
Alexander S. SobolevAlexander S. Sobolev
Alexander S. Sobolev
Background: The most attractive features of Auger electrons (AEs) in cancer therapy are their extremely short range and sufficiently high linear energy transfer (LET) for a majority of them. The cytotoxic effects of AE emitters can be realized only in close vicinity to sensitive cellular targets and they are negligible if the emitters are located outside the cell. The nucleus is considered the compartment most sensitive to high LET particles. Therefore, the use of AE emitters could be most useful in specific recognition of a cancer cell and delivery of AE emitters into its nucleus. Purpose: This review describes the studies aimed at developing effective anticancer agents for the delivery of AE emitters to the nuclei of target cancer cells. The use of peptide-based conjugates, nanoparticles, recombinant proteins, and other constructs for AE emitter targeted intranuclear delivery as well as their advantages and limitations are discussed. Conclusion: Transport from the cytoplasm to the nucleus along with binding to the cancer cell is one of the key stages in the delivery of AE emitters; therefore, several constructs for exploitation of this transport have been developed. The transport is carried out through a nuclear pore complex (NPC) with the use of specific amino acid nuclear localization sequences (NLS) and carrier proteins named importins, which are located in the cytosol. Therefore, the effectiveness of NLS-containing delivery constructs designed to provide energy-dependent transport of AE emitter into the nuclei of cancer cells also depends on their efficient entry into the cytosol of the target cell.